Suchergebnisse - "Rouzade‐Dominguez, Marie‐Laure"

PubPharm (21)

1

The Generation program : Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2

enthalten in: Alzheimer's & Dementia | 2020

von Tariot, P. | Borowsky, B. | Liu, F. | +11

2

Umibecestat in the API Generation program : Worsening in RBANS and/or CDR on treatment reverses after wash‐out

enthalten in: Alzheimer's & Dementia | 2020

von Graf, A. | Riviere, M. | Liu, F. | +12

3

The API Generation program : Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes

enthalten in: Alzheimer's & Dementia | 2020

von Reiman, E. | Tariot, P. | Borowsky, B. | +18

4

The API Generation program : Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2

enthalten in: Alzheimer's & Dementia | 2020

von Rouzade‐Dominguez, M. | Riviere, M. | Borowsky, B. | +12

5

The Alzheimer's Prevention Initiative Generation Program : Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

enthalten in: Alzheimer's & dementia (New York, N. Y.) | 2019

von Lopez Lopez, C. | Tariot, P. | Caputo, A. | +13

6

FTS3‐01‐01 : UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY IN RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS

enthalten in: Alzheimer's & Dementia | 2019

von Graf, A. | Kolly, C. | Dubost, V. | +9

7

The Alzheimer's Prevention Initiative Generation Program : Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

enthalten in: Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2019

von Lopez Lopez, C. | Tariot, P. | Caputo, A. | +13

8

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

enthalten in: EMBO molecular medicine | 2018

von Neumann, U. | Ufer, M. | Jacobson, L. | +29

CommentIn: EMBO Mol Med. 2018 Nov;10(11):. - PMID 30322841

9

The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease

enthalten in: Neurogastroenterology and motility | 2017

von Rouzade-Dominguez, M. | Pezous, N. | David, O. | +7

10

[O2–17–05] : RATIONALE FOR CNP520 DOSE SELECTION FOR THE PIVOTAL CLINICAL PROGRAM IN PRECLINICAL AD

enthalten in: Alzheimer's & Dementia | 2017

von Lopez‐Lopez, C. | Ufer, M. | Rouzade‐Dominguez, M. | +9